Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6643718 | 0.94 | CYP1A2 (0.59) | ALDH1A1CYP1A2CYP2C9HPGDCYP2D6 | |
| SCHEMBL1641137 | 0.88 | LTA4H (0.61) | ALDH1A1MAPTLMNALTA4HPTGS1 | |
| SCHEMBL6408582 | 0.87 | LTA4H (0.60) | ALDH1A1MAPTLMNALTA4HPTGS1 | |
| SCHEMBL3382465 | 0.86 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2MAPTKCNJ1LTA4H | |
| SCHEMBL25398564 | 0.85 | KDM4E (0.50) | ALDH1A1CYP1A2CYP2C9HPGDSMN1; SMN2 | |
| SCHEMBL16973009 | 0.82 | LTA4H (0.46) | ALDH1A1MAPTLMNAKCNJ1LTA4H | |
| SCHEMBL22171219 | 0.82 | MAPT (0.56) | ALDH1A1CYP1A2CYP2C9CYP2D6CYP2C19 | |
| SCHEMBL13736688 | 0.81 | CD38 (0.41) | ALDH1A1CYP1A2CYP2C9HPGDMAPT | |
| SCHEMBL519451 | 0.81 | LTA4H (0.71) | ALDH1A1SMN1; SMN2MAPTLMNAKCNJ1 | |
| SCHEMBL15972100 | 0.79 | ALDH1A1 (0.57) | ALDH1A1CYP1A2CYP2C9HPGDCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117580829-A | Quinoline and azaquinolines as inhibitors of CD38 | 勃林格英格翰国际有限公司 | 2024-02-20 | — | — | CN | disclosed |
| EP-4284511-A1 | QUINOLINES AND AZAQUINOLINES AS INHIBITORS OF CD38 | Boehringer Ingelheim International GmbH (DE) | 2023-12-06 | — | — | EP | disclosed |
| WO-2022165114-A1 | QUINOLINES AND AZAQUINOLINES AS INHIBITORS OF CD38 | RIBON THERAPEUTICS, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| US-20100056524-A1 | Compound | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-03-04 | — | — | US | disclosed |
| US-20100056524-A1 | Compound | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-03-04 | — | — | US | disclosed |
| US-20100056524-A1 | Compound | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-03-04 | — | — | US | disclosed |
| WO-2009122180-A1 | PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES | MEDICAL RESEARCH COUNCIL (GB) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056524-A1 | Compound | NR3C2, NR3C1, NR2E3 | ALDH1A1 2440/4885CYP1A2 629/4885CYP2C9 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.